CEBPA and acute myeloid leukemia: The 2022 WHO classification of AML has incorporated genomic alterations in NPM1, CEBPA, and secondary‐type mutations in ASXL1, BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2 owing to their association with distinct clinical features and outcomes.20